1st Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece.
Med Sci Monit. 2010 Aug;16(8):CS100-2.
Romiplostim is a second-generation thrombopoietic receptor agonist that exerts its therapeutic effect by stimulating megakaryopoiesis.
We report a patient with immune thrombocytopenic purpura refractory to other therapies including splenectomy, which was successfully managed with romiplostim. More specifically, the patient's platelet count showed a 3-fold increase within 7 days following the first dose of romiplostim (from 33 x 10(9)/l to 96 x 10(9)/l).
Romiplostin is a new trombopoietin peptide mimetic drug, which seems to be very effective for the management of refractory chronic ITP in adults.
罗米司亭是一种第二代促血小板生成素受体激动剂，通过刺激巨核细胞生成发挥治疗作用。
我们报告了一例对包括脾切除术在内的其他治疗方法均无效的免疫性血小板减少性紫癜患者，该患者使用罗米司亭成功得到治疗。更具体地说，患者的血小板计数在首次使用罗米司亭后 7 天内增加了 3 倍（从 33×10(9)/l 增加到 96×10(9)/l）。
罗米司亭是一种新型的促血小板生成素肽模拟药物，似乎对成人难治性慢性 ITP 的治疗非常有效。
Zotero 插件